Upstate New York/Vermont Chapter
www.lls.org/uny
Local Staff Contacts
Upstate New York/Vermont
5 Computer Drive West Suite 100
Albany, NY 12205
(518) 438-3583 (phone)- Executive Director
- Maureen O'brien-Thornton
- maureen.thornton@lls.org
- 518-438-3583 (phone)
- Special Events Campaign Manager
- Andrea Googas
- andrea.googas@lls.org
- 518-438-3583 (phone)
- Vermont Representative
- Gail Deuso
- gail.deuso@lls.org
- 802-233-0014 (phone)
- Office Manager
- Karin Bootier
- karin.bootier@lls.org
- 518-438-3583 (phone)
- Campaign Assistant
- Karla Pagan
- karla.pagan@lls.org
- 518-438-3583 (phone)
- Light The Night Campaign Manager
- Tena Bunnell
- tena.bunnell@lls.org
- 518-438-3583 (phone)
- Campaign Coordinator
- Brandy Farber
- brandy.farber@lls.org
- 518-438-3583 (phone)
- Campaign Manager
- Kristi Miller
- kristi.miller@lls.org
- 518-438-3583 (phone)
- Patient Services Manager
- Michael Grignon
- michael.grignon@lls.org
- 518-438-3583 (phone)
- Campaign Coordinator, Team In Training
- Charly Mallet
- charly.mallet@lls.org
- 518-438-3583 (phone)
About the Upstate New York/Vermont Chapter
The Leukemia & Lymphoma Society's Upstate New York/Vermont Chapter was founded in 1975 to serve residents who have been touched by one of the blood cancers: leukemia, lymphoma, Hodgkin's disease and myeloma. The chapter serves the following twenty counties in Upstate New York: Albany, Clinton, Columbia, Delaware, Dutchess, Essex, Franklin, Fulton, Greene, Hamilton, Montgomery, Otsego, Rensselaer, Saratoga, Schenectady, Schoharie, Sullivan, Ulster, Warren, and Washington. In addition, we serve all counties in Vermont.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (LLS), based in White Plains, NY, is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since it was founded in 1949, LLS has invested more than $750 million in research specifically targeting blood cancers.
